Australian biotech market today 13.03.09
Friday, 13 March, 2009
Biotech and pharma stocks were up 1.5 per cent on trading at 2pm compared to a rise in the All Ordinaries of three per cent, on a good day for the Australian sharemarket overall.
Alchemia (ASX:ACL) is up 5c on news that its manufacturing partner Dr Reddy’s Laboratories had filed a new drug application with the US FDA for a generic version of fondaparinux, an anti-coagulant used for treating blood clots.
pSivida (ASX:PVA) was up eight per cent to $1 following its report of good interim results in a Phase II trial of an intra-vitreal insert for diabetic macular oedema.
CSL (ASX:CSL) is up 40c but is still down on its year high of $38.50, while Sonic Healthcare recovered 40c on yesterday’s year low of $9.96.
Acrux (ASX:ACR) and Cellestis (ASX:CST) were up slightly on very small volumes.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
